Navigation Links
Hagens Berman Sobol Shapiro: Vytorin and Zetia Makers Settle Class-Action Suit With Proposed $41.5 Million

BOSTON, Aug. 5 /PRNewswire/ --- Attorneys representing consumers and third-party payors today announced a proposed $41.5 million settlement with drug manufacturers Merck & Co. (NYSE: MRK) and Schering-Plough Corporation (NYSE: SGP) to settle allegations the companies suppressed critical information about the efficacy and safety of prescription drugs Vytorin and Zetia. Merck and Schering-Plough previously settled similar claims with 35 states and the District of Columbia for $5.4 million.


Hagens Berman Sobol Shapiro (HBSS), counsel for a nationwide class of third-party payors, brought the suit against manufacturers along with consumers in January 2008. Thomas M. Sobol, lead attorney on the case, hailed the agreement as an excellent result for plaintiffs.

"I am very pleased that we reached a comprehensive settlement that serves our clients' interest so well," Sobol said. "This settlement also reflects the vital role private litigation plays in holding pharmaceutical companies accountable when the FDA cannot."

Vytorin is the combination of prescription pills Zetia and Zocor, a statin available as a generic drug for about one-third the cost. The Food and Drug Administration (FDA) approved Zetia and Vytorin on the basis that the drugs reduced "bad" - or LDL - cholesterol. Defendants failed to present any evidence to the FDA that these drugs actually reduced the risk of heart disease or strokes.

Plaintiffs allege Merck and Schering-Plough created a joint venture in an attempt to protect profits from Zocor, Merck's hugely profitable cholesterol drug, which would otherwise lose patent protection in January 2006. In an effort to stem the eventual loss of sales to a generic form of Zocor, defendants marketed Vytorin as a single pill and an improvement over Zocor alone.

The lawsuit alleges that an internal study showed the combination-drug, Vytorin was actually less effective in reducing arterial plaque buildup than Zocor alone. The study also showed that Vytorin posed serious safety concerns. Plaintiffs claim the drug makers did not disclose the results of this study and instead sought to delay and conceal the negative results, causing consumers and third-party payors to pay for unnecessary prescriptions of Vytorin and Zetia.

The lawsuit, filed under the Racketeering Influenced and Corrupt Organizations Act (RICO), as well as the consumer protection statutes of New Jersey, California, Florida, Texas and Massachusetts is pending in United States District Court for the District of New Jersey.

The $41.5 million settlement is pending court approval. A preliminary approval hearing will be scheduled in the next month, followed by notice to members of the class.

You can review court documents on this case at

About Hagens Berman Sobol Shapiro

Hagens Berman Sobol Shapiro is based in Seattle with offices in Chicago, Boston, Los Angeles, Phoenix and San Francisco. Since the firm's founding in 1993, it has developed a nationally recognized practice in class action and complex litigation. Among recent successes, HBSS has negotiated a pending $300 million settlement as lead counsel in the DRAM memory antitrust litigation; a $340 million recovery on behalf of Enron employees which is awaiting distribution; a $150 million settlement involving charges of illegally inflated charges for the drug Lupron, and served as co-counsel on the Visa/Mastercard litigation which resulted in a $3 billion settlement, the largest anti-trust settlement to date. HBSS also served as counsel in a $850 million settlement in the Washington Public Power Supply litigation and represented Washington and 12 other states in lawsuits against the tobacco industry that resulted in the largest settlement in the history of litigation. For a complete listing of HBSS cases, visit


    Thomas M. Sobol (617) 482-3700
    Hagens Berman Sobol Shapiro

    Mark Firmani (206) 443-9357
    Firmani + Associates, Inc.

SOURCE Hagens Berman Sobol Shapiro
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Rulings Send Lawsuits Against State Farm, American Family Back to Court, Hagens Berman Sobol Shapiro Announces
2. Hagens Berman Sobol Shapiro: Judge Orders Double Damages, Issues Stinging Rebuke in Average Wholesale Price Case
3. Hagens Berman Sobol Shapiro Announces Investigation Into Marketing of Vytorin and Zetia
4. CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough
5. Anatomist Dr. Gunther von Hagens Clarifies: Plastinates Not For Sale
6. Hagens Berman: Eleven Defendants Settle in Average Wholesale Price Litigation
7. Hagens Berman Sobol Shapiro: Nationwide Class Action Certified in Average Wholesale Price Litigation
8. Gunther Von Hagens BODY WORLDS Exhibitions Mark 25th Million Visitor Milestone
9. Gunther von Hagens BODY WORLDS Exhibitions Welcome Specimens From Worlds First Living Body Donor for Plastination
10. Hagens Berman Appointed Co-Lead Counsel in Case Against Schering-Plough and Merck
11. Hagens Berman Sobol Shapiro: Attorneys Representing Consumers Prepare for $12 Billion RICO Trial Against McKesson for Alleged Drug Price Manipulation
Post Your Comments:
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
Breaking Medicine Technology: